Limonin, an AMPK Activator, Inhibits Hepatic Lipid Accumulation in High Fat Diet Fed Mice

NAFLD is the most prevalent liver disease in human history. The treatment is still limited yet. In the current study, we reported that limonin inhibited hepatic lipid accumulation and fatty acid synthesis in HFD fed mice. Using AMPK inhibitor and AMPK deficient , we revealed the effect was dependent...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 13; p. 833705
Main Authors Wang, Si-Wei, Lan, Tian, Chen, Hang-Fei, Sheng, Hao, Xu, Chun-Yi, Xu, Li-Feng, Zheng, Fang, Zhang, Feng
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 24.01.2022
Subjects
AMPK
limonin
lipid accumulation
NAFLD
Pharmacology
SREBP
AMPK
NAFLD
SREBP
limonin
lipid accumulation
Online AccessGet full text

Cover

More Information
Summary:NAFLD is the most prevalent liver disease in human history. The treatment is still limited yet. In the current study, we reported that limonin inhibited hepatic lipid accumulation and fatty acid synthesis in HFD fed mice. Using AMPK inhibitor and AMPK deficient , we revealed the effect was dependent on the activation of AMPK. We found that limonin activated AMPK through inhibition of cellular energy metabolism and increasing ADP:ATP ratio. Furthermore, the treatment of limonin induced AMPK mediated suppression of the transcriptional activity of SREBP1/2. Our study suggests that limonin may a promising therapeutic agent for the treatment of NAFLD.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Menghao Huang, Indiana University School of Medicine, United States
This article was submitted to Gastrointestinal and Hepatic Pharmacology, a section of the journal Frontiers in Pharmacology
Reviewed by: Hu Li, Chinese Academy of Medical Sciences and Peking Union Medical College, China
Chuanpeng Dong, Purdue University Indianapolis, United States
Jinan Li, Indiana University School of Medicine, United States
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2022.833705